Levodopa-Loaded 3D-Printed Poly (Lactic) Acid/Chitosan Neural Tissue Scaffold as a Promising Drug Delivery System for the Treatment of Parkinson’s Disease
Source abstract
Abstract
Parkinson’s disease, the second most common neurodegenerative disease in the world, develops due to decreased dopamine levels in the basal ganglia. Levodopa, a dopamine precursor used in the treatment of Parkinson’s disease, can be used as a drug delivery system. This study presents an approach to the use of 3D-printed levodopa-loaded neural tissue scaffolds produced with polylactic acid (PLA) and chitosan (CS) for the treatment of Parkinson’s disease. Surface morphology and pore sizes were examined by scanning electron microscopy (SEM). Average pore sizes of 100–200 µm were found to be ideal for tissue engineering scaffolds, allowing cell penetration but not drastically altering the mechanical properties. It was observed that the swelling and weight loss behaviors of the scaffolds increased after the addition of CS to the PLA. Levodopa was released from the 3D-printed scaffolds in a controlled manner for 14 days, according to a Fickian diffusion mechanism. Mesenchymal stem cells (hAD-MSCs) derived from human adipose tissue were used in MTT analysis, fluorescence microscopy and SEM studies and confirmed adequate biocompatibility. Overall, the obtained results show that PLA/CS 3D-printed scaffolds have an alternative use for the levodopa delivery system for Parkinson’s disease in neural tissue engineering applications.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: biodegradable polymer synthesis and properties · Electrospun Nanofibers in Biomedical Applications · Nerve injury and regeneration
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Center for Nanotechnology & Biomaterials Application and Research (NBUAM), Marmara University, İstanbul 34000, Turkey
Department of Bioengineering, Faculty of Engineering, Marmara University, İstanbul 34000, Turkey
Department of Metallurgical and Materials Engineering, Faculty of Technology, Marmara University, İstanbul 34000, Turkey
Department of Pharmacology, Faculty of Pharmacy, Marmara University, İstanbul 34000, Turkey
Department of Biochemistry, School of Medicine, Genetic and Metabolic Diseases Research and Investigation Center, Marmara University, Istanbul 34000, Turkey
Department of Mechanical Engineering, University College London, Torrington Place, London WC1E 7JE, UK
Faculty of Applied Chemistry and Material Science, University Politehnica of Bucharest, Spl. Independentei 313, 060042 Bucharest, Romania
Academy of Romanian Scientists, Ilfov St. 3, 060042 Bucharest, Romania
Funding
BAPKO, Marmara University;
References (51)
Show source-provided references
1. Levodopa delivery systems for the treatment of Parkinson’s disease: An overview10.1016/j.ijpharm.2009.07.026 ↗
2. Parkinson disease10.1038/nrdp.2017.13 ↗
3. Epidemiology of Parkinson’s disease10.1007/s00702-017-1686-y ↗
4. Electrospun Zein nanofibers as drug carriers for controlled delivery of Levodopa in Parkinson syndrome10.1088/2053-1591/ab16bf ↗
5. Levodopa in Parkinson’s disease: From the past to the future10.1517/14656561003598919 ↗
6. Levodopa Incorporation in Alginate Membranes for Drug Delivery Studies10.4028/www.scientific.net/AMR.749.423 ↗
7. Cesur, S., Cam, M.E., Sayın, F.S., Su, S., and Gunduz, O. (2020). Controlled Release of Metformin Loaded Polyvinyl Alcohol (PVA) Microbubble/Nanoparticles Using Microfluidic Device for the Treatment of Type 2 Diabetes Mellitus. Bioinformatics and Biomedical Engineering, Proceedings of the 8th International Work-Conference, Granada, Spain, 6–8 May 2020, Springer.10.1007/978-3-030-45385-5_17 ↗
8. Ilhan, E., Ulag, S., Sahin, A., Ekren, N., Kilic, O., Oktar, F.N., and Gunduz, O. (2020). Production of 3D-Printed Tympanic Membrane Scaffolds as a Tissue Engineering Applicattion. Bioinformatics and Biomedical Engineering, Springer Nature.10.1007/978-3-030-45385-5_16 ↗
9. Preparation and characterization of electrospun polylactic acid/sodium alginate/orange oyster shell composite nanofiber for biomedical application10.1007/s41779-019-00363-1 ↗
10. Poly(lactic acid) modifications10.1016/j.progpolymsci.2009.12.003 ↗
11. Poly(lactic acid)/chitosan hybrid nanoparticles for controlled release of anticancer drug10.1016/j.msec.2014.10.048 ↗
12. Chitosan: A potential biopolymer for wound management10.1016/j.ijbiomac.2017.04.047 ↗
13. Experimental and theoretical investigation of the fluid behavior during polymeric fiber formation with and without pressure10.1063/1.5110965 ↗
14. Rasagiline-encapsulated chitosan-coated PLGA nanoparticles targeted to the brain in the treatment of parkinson’s disease10.1080/10826076.2017.1343735 ↗
15. Three-Dimensional Scaffolds for Tissue Engineering Applications: Role of Porosity and Pore Size10.1089/ten.teb.2012.0437 ↗
16. Aranci, K., Uzun, M., Su, S., Cesur, S., Ulag, S., Amin, A., Guncu, M., Aksu, B., Kolayli, S., and Ustundag, C. (2020). 3D Propolis-Sodium Alginate Scaffolds: Influence on Structural Parameters, Release Mechanisms, Cell Cytotoxicity and Antibacterial Activity. Molecules, 25.10.3390/molecules25215082 ↗
17. Potent bioactive bone cements impregnated with polystyrene-g-soybean oil-AgNPs for advanced bone tissue applications10.1080/10667857.2019.1661157 ↗
18. 3D printed artificial cornea for corneal stromal transplantation10.1016/j.eurpolymj.2020.109744 ↗
19. Release behaviour and toxicity evaluation of levodopa from carboxylated single-walled carbon nanotubes10.3762/bjnano.6.23 ↗
20. A novel treatment strategy for preterm birth: Intra-vaginal progesterone-loaded fibrous patches10.1016/j.ijpharm.2020.119782 ↗
21. Fabrication, characterization and fibroblast proliferative activity of electrospun Achillea lycaonica-loaded nanofibrous mats10.1016/j.eurpolymj.2019.109239 ↗
22. Accelerated diabetic wound healing by topical application of combination oral antidiabetic agents-loaded nanofibrous scaffolds: An in vitro and in vivo evaluation study10.1016/j.msec.2020.111586 ↗
23. 3D cell bioprinting for regenerative medicine research and therapies10.1142/S1568558611000301 ↗
24. ‘Printability’ of Candidate Biomaterials for Extrusion Based 3D Printing: State-of-the-Art10.1002/adhm.201700264 ↗
25. Lukić, M., Clarke, J., Tuck, C., Whittow, W., and Wells, G. (2015). Printability of elastomer latex for additive manufacturing or 3D printing. J. Appl. Polym. Sci., 133.10.1002/app.42931 ↗
26. Production and characterization of elastomeric cardiac tissue-like patches for Myocardial Tissue Engineering10.1016/j.polymertesting.2020.106613 ↗
27. Fabrication of tissue-engineered tympanic membrane patches using 3D-Printing technology10.1016/j.jmbbm.2020.104219 ↗
28. Preparation and antibacterial properties of ε-polylysine-containing gelatin/chitosan nanofiber films10.1016/j.ijbiomac.2020.08.152 ↗
29. Fabrication of Electrospun Levodopa-Carbidopa Fixed-Dose Combinations10.1007/s42765-020-00031-1 ↗
30. Hydroxyapatite/poly(ε-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery10.1016/j.biomaterials.2003.07.003 ↗
31. Development of Satureja cuneifolia-loaded sodium alginate/polyethylene glycol scaffolds produced by 3D-printing technology as a diabetic wound dressing material10.1016/j.ijbiomac.2020.06.086 ↗
32. Surface functionalization of 3D printed polymer scaffolds to augment stem cell response10.1016/j.matdes.2018.11.018 ↗
33. Chitosan Hydrogels for Chondroitin Sulphate Controlled Release: An Analytical Characterization10.1155/2014/808703 ↗
34. The performance of laminin-containing cryogel scaffolds in neural tissue regeneration10.1016/j.biomaterials.2011.01.049 ↗
35. Neurite bridging across micropatterned grooves10.1016/j.biomaterials.2005.06.035 ↗
36. Jian, Y.-T., Yang, Y., Tian, T., Stanford, C., Zhang, X.-P., and Zhao, K. (2015). Effect of Pore Size and Porosity on the Biomechanical Properties and Cytocompatibility of Porous NiTi Alloys. PLoS ONE, 10.10.1371/journal.pone.0128138 ↗
37. 3D printed biodegradable composites: An insight into mechanical properties of PLA/chitosan scaffold10.1016/j.polymertesting.2020.106722 ↗
38. Optimization and reliability analysis to improve surface quality and mechanical characteristics of heat-treated fused filament fabricated parts10.1007/s00170-018-03276-8 ↗
39. Processing, tensile and morphological characteristics of polylactic acid/chitosan biocomposites prepared by melt compounding technique10.1063/5.0016532 ↗
40. Effect of Filler Loading on Curing Characteristic and Tensile Properties of Palygorskite Natural Rubber Nanocomposites10.1016/j.proche.2016.03.023 ↗
41. Preparation and Characterization of Vancomycin-Loaded ElectrospunRana chensinensisSkin Collagen/Poly(L-lactide) Nanofibers for Drug Delivery
42. Structural, mechanical and swelling characteristics of 3D scaffolds from chitosan-agarose blends10.1016/j.carbpol.2018.10.002 ↗
43. Fabrication and characterization of nanofibers based on poly(lactic acid)/chitosan blends by electrospinning and their functionalization with phospholipase A110.1007/s12221-017-6953-x ↗
44. Investigating the morphological, mechanical and degradation properties of scaffolds comprising collagen, gelatin and elastin for use in soft tissue engineering10.1016/j.jmbbm.2012.02.028 ↗
45. Polymer Scaffolds for Biomaterials Applications10.1021/ma901530r ↗
46. Development of Injectable Biodegradable Multi-Arms PEG-Based Hydrogels: Swelling and Degradation Investigations10.1002/masy.201051033 ↗
47. Drug release behavior of beads and microgranules of chitosan10.1016/S0142-9612(99)00263-X ↗
48. Formulation study and drug release mechanism of a new theophylline sustained-release preparation10.1016/j.ijpharm.2005.07.022 ↗
49. Electrospun polylactic acid-chitosan composite: A bio-based alternative for inorganic composites for advanced application10.1007/s10856-018-6146-1 ↗
50. Fabrication of chitosan/poly(lactic acid)/graphene oxide/TiO2 composite nanofibrous scaffolds for sustained delivery of doxorubicin and treatment of lung cancer10.1016/j.ijbiomac.2017.08.048 ↗
51. Development of a controlled-release anti-parkinsonian nanodelivery system using levodopa as the active agent10.2147/IJN.S39740 ↗